DXR Daxor Corp.

Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 10th through a virtual format with on-demand video presentations.

Mr. Feldschuh will report on the many accomplishments of the Company in the areas of financial performance, commercialization of products, groundbreaking research and product development, and new prospective medical trials for the use of Daxor’s BVA-100® blood test in the management of critical care, COVID-19, and heart failure with leading institutions.

The presentation will be available for on-demand listening beginning at 7:00 AM ET on Tuesday, March 9, 2021 and will be available for 90 days. For those interested in viewing Mr. Feldschuh's presentation, conference registration can be accessed . Mr. Feldschuh will also be available for virtual one-on-one meetings on March 9-10, and meeting requests can be made once registered.

Event: H.C. Wainwright Global Life Sciences Conference

Date: March 9th -10th

Register here:

Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing .

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at .

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560



EN
04/03/2021

Underlying

DXRDaxor Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Daxor Corp.

 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients ...

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert...

September 4, 2025 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global...

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning Friday, September 5 at 7:00 a.m. ET. Investors who wish to listen to the Company’s presentation can...

September 3, 2025 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Hal...

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it p...

September 2, 2025 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now...

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Da...

August 12, 2025 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, B...

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA™ device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a b...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch